Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

INTRODUCTION: Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Schafer, Peter H., Kivitz, Alan J., Ma, Jianglin, Korish, Shimon, Sutherland, Donna, Li, Li, Azaryan, Ada, Kosek, Jolanta, Adams, Mary, Capone, Lori, Hur, Eun Mi, Hough, Douglas R., Ringheim, Garth E.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021855/
https://ncbi.nlm.nih.gov/pubmed/31721017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00182-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados